Advanced

EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Gülfe, Anders LU ; KARLSSON WALLMAN, JOHAN LU and Kristensen, Lars Erik (2016) In Arthritis Research and Therapy 18(1).
Abstract
The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Arthritis Research and Therapy
volume
18
issue
1
publisher
BioMed Central
external identifiers
  • pmid:26892115
  • scopus:84959449364
  • wos:000370836900001
ISSN
1478-6362
DOI
10.1186/s13075-016-0950-0
language
English
LU publication?
yes
id
78e36753-0dbd-4f59-831c-f8468e5fe341 (old id 8825071)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26892115?dopt=Abstract
date added to LUP
2016-03-03 12:33:53
date last changed
2017-11-19 04:17:48
@article{78e36753-0dbd-4f59-831c-f8468e5fe341,
  abstract     = {The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.},
  articleno    = {51},
  author       = {Gülfe, Anders and KARLSSON WALLMAN, JOHAN and Kristensen, Lars Erik},
  issn         = {1478-6362},
  language     = {eng},
  number       = {1},
  publisher    = {BioMed Central},
  series       = {Arthritis Research and Therapy},
  title        = {EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.},
  url          = {http://dx.doi.org/10.1186/s13075-016-0950-0},
  volume       = {18},
  year         = {2016},
}